These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35527737)

  • 1. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.
    Maschio C; Ni R
    Front Aging Neurosci; 2022; 14():838034. PubMed ID: 35527737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Jul; 12(13):2437-2447. PubMed ID: 34152739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
    Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
    Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and preclinical characterization of [
    Kroth H; Oden F; Molette J; Schieferstein H; Capotosti F; Mueller A; Berndt M; Schmitt-Willich H; Darmency V; Gabellieri E; Boudou C; Juergens T; Varisco Y; Vokali E; Hickman DT; Tamagnan G; Pfeifer A; Dinkelborg L; Muhs A; Stephens A
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2178-2189. PubMed ID: 31264169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K; Ono M; Kubota M; Kitamura S; Takahata K; Seki C; Takado Y; Shinotoh H; Sano Y; Yamamoto Y; Matsuoka K; Takuwa H; Shimojo M; Takahashi M; Kawamura K; Kikuchi T; Okada M; Akiyama H; Suzuki H; Onaya M; Takeda T; Arai K; Arai N; Araki N; Saito Y; Trojanowski JQ; Lee VMY; Mishra SK; Yamaguchi Y; Kimura Y; Ichise M; Tomita Y; Zhang MR; Suhara T; Shigeta M; Sahara N; Higuchi M; Shimada H
    Neuron; 2021 Jan; 109(1):42-58.e8. PubMed ID: 33125873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of tau PET molecular imaging.
    Cassinelli Petersen G; Roytman M; Chiang GC; Li Y; Gordon ML; Franceschi AM
    Curr Opin Neurol; 2022 Apr; 35(2):230-239. PubMed ID: 35191407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [
    Tezuka T; Takahata K; Seki M; Tabuchi H; Momota Y; Shiraiwa M; Suzuki N; Morimoto A; Nakahara T; Iwabuchi Y; Miura E; Yamamoto Y; Sano Y; Funaki K; Yamagata B; Ueda R; Yoshizaki T; Mashima K; Shibata M; Oyama M; Okada K; Kubota M; Okita H; Takao M; Jinzaki M; Nakahara J; Mimura M; Ito D
    Brain Commun; 2021; 3(4):fcab190. PubMed ID: 34632382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils.
    Zhou Y; Li J; Nordberg A; Ågren H
    ACS Chem Neurosci; 2021 Sep; 12(18):3487-3496. PubMed ID: 34464084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.
    Fodero-Tavoletti MT; Furumoto S; Taylor L; McLean CA; Mulligan RS; Birchall I; Harada R; Masters CL; Yanai K; Kudo Y; Rowe CC; Okamura N; Villemagne VL
    Alzheimers Res Ther; 2014; 6(1):11. PubMed ID: 24572336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging pathological tau in atypical parkinsonisms: A review.
    Mena AM; Strafella AP
    Clin Park Relat Disord; 2022; 7():100155. PubMed ID: 35880206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.
    Wu L; Gilyazova N; Ervin JF; Wang SJ; Xu B
    ACS Chem Neurosci; 2022 Dec; 13(23):3281-3290. PubMed ID: 36350059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study.
    Holland N; Malpetti M; Rittman T; Mak EE; Passamonti L; Kaalund SS; Hezemans FH; Jones PS; Savulich G; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2022 Mar; 145(1):340-348. PubMed ID: 34398211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Arai T; Ikeda K; Akiyama H; Tsuchiya K; Iritani S; Ishiguro K; Yagishita S; Oda T; Odawara T; Iseki E
    Acta Neuropathol; 2003 May; 105(5):489-98. PubMed ID: 12677450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective tau tyrosine nitration in non-AD tauopathies.
    Reyes JF; Geula C; Vana L; Binder LI
    Acta Neuropathol; 2012 Jan; 123(1):119-32. PubMed ID: 22057784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
    Ono M; Sahara N; Kumata K; Ji B; Ni R; Koga S; Dickson DW; Trojanowski JQ; Lee VM; Yoshida M; Hozumi I; Yoshiyama Y; van Swieten JC; Nordberg A; Suhara T; Zhang MR; Higuchi M
    Brain; 2017 Mar; 140(3):764-780. PubMed ID: 28087578
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Graham TJA; Lindberg A; Tong J; Stehouwer JS; Vasdev N; Mach RH; Mathis CA
    J Med Chem; 2023 Aug; 66(15):10628-10638. PubMed ID: 37487189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
    Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils.
    Li J; Kumar A; Långström B; Nordberg A; Ågren H
    ACS Chem Neurosci; 2023 Sep; 14(18):3528-3539. PubMed ID: 37639522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropathology and emerging biomarkers in corticobasal syndrome.
    Koga S; Josephs KA; Aiba I; Yoshida M; Dickson DW
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(9):919-29. PubMed ID: 35697501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.